1 T moderate intensity static magnetic field affects Akt/mTOR pathway and increases the antitumor efficacy of mTOR inhibitors in CNE-2Z cells

详细信息    查看全文

• 作者：Lei Zhang ; Xingxing Yang ; Juanjuan Liu ; Yan Luo ; Zhiyuan Li ; Xinmiao Ji…
• 关键词：Static magnetic field ; Cell proliferation ; mTOR ; mTOR inhibitor ; Feedback reactivation ; 稳态磁场
细胞增殖 ; mTOR ; mTOR抑制剂 负反馈
• 刊名：Chinese Science Bulletin
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：60
• 期：24
• 页码：2120-2128
• 全文大小：3,399 KB
• 参考文献：1.Grassi C, D’Ascenzo M, Torsello A et al (2004) Effects of 50 Hz electromagnetic fields on voltage-gated Ca2+ channels and their role in modulation of neuroendocrine cell proliferation and death. Cell Calcium 35:307–315CrossRef
  2.Rosen AD, Chastney EE (2009) Effect of long term exposure to 0.5 T static magnetic fields on growth and size of GH3 cells. Bioelectromagnetics 30:114–119CrossRef
  3.Zhang M, Li X, Bai L et al (2013) Effects of low frequency electromagnetic field on proliferation of human epidermal stem cells: an in vitro study. Bioelectromagnetics 34:74–80CrossRef
  4.Sullivan K, Balin AK, Allen RG (2011) Effects of static magnetic fields on the growth of various types of human cells. Bioelectromagnetics 32:140–147CrossRef
  5.Aldinucci C, Garcia JB, Palmi M et al (2003) The effect of strong static magnetic field on lymphocytes. Bioelectromagnetics 24:109–117CrossRef
  6.Ghibelli L, Cerella C, Cordisco S et al (2006) NMR exposure sensitizes tumor cells to apoptosis. Apoptosis 11:359–365CrossRef
  7.Sun Z, Wang Z, Liu X et al (2015) New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Anticancer Drugs 26:1–14CrossRef
  8.Nakahara T, Yaguchi H, Yoshida M et al (2002) Effects of exposure of CHO-K1 cells to a 10-T static magnetic field. Radiology 224:817–822CrossRef
  9.Zhao G, Chen S, Zhao Y et al (2010) Effects of 13 T static magnetic fields (smf) in the cell cycle distribution and cell viability in immortalized hamster cells and human primary fibroblasts cells. Plasma Sci Technol 12:123–128CrossRef
  10.Zito CR, Jilaveanu LB, Anagnostou V et al (2012) Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS ONE 7:e31331CrossRef
  11.Ocana A, Vera-Badillo F, Al-Mubarak M et al (2014) Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS ONE 9:e95219CrossRef
  12.Porta C, Paglino C, Mosca A (2014) Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 4:64CrossRef
  13.Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9–22CrossRef
  14.Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307–318CrossRef
  15.Sabatini DM, Erdjument-Bromage H, Lui M et al (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35–43CrossRef
  16.Sarbassov DD, Ali SM, Kim DH et al (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296–1302CrossRef
  17.Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21–35CrossRef
  18.Sarbassov DD, Guertin DA, Ali SM et al (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101CrossRef
  19.Gadgeel SM, Wozniak A (2013) Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer 14:322–332CrossRef
  20.Chresta CM, Davies BR, Hickson I et al (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70:288–298CrossRef
  21.Liu Q, Xu C, Kirubakaran S et al (2013) Characterization of Torin 2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res 73:2574–2586CrossRef
  22.Thoreen CC, Kang SA, Chang JW et al (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284:8023–8032CrossRef
  23.English DP, Roque DM, Carrara L et al (2013) HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol Oncol 131:753–758CrossRef
  24.Schenone S, Brullo C, Musumeci F et al (2011) ATP-competitive inhibitors of mTOR: an update. Curr Med Chem 18:2995–3014CrossRef
  25.Wan X, Harkavy B, Shen N et al (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26:1932–1940CrossRef
  26.Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC et al (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1:248–259CrossRef
  27.Wander SA, Hennessy BT, Slingerland JM (2011) Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 121:1231–1241CrossRef
  28.Fumarola C, Bonelli MA, Petronini PG et al (2014) Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol 90:197–207CrossRef
  29.Zardavas D, Fumagalli D, Loi S (2012) Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2−) breast cancers? Curr Opin Oncol 24:623–634CrossRef
  30.Hao Q, Wenfang C, Xia A et al (2011) Effects of a moderate-intensity static magnetic field and adriamycin on K562 cells. Bioelectromagnetics 32:191–199CrossRef
  31.Gray JR, Frith CH, Parker JD (2000) In vivo enhancement of chemotherapy with static electric or magnetic fields. Bioelectromagnetics 21:575–583CrossRef
  32.Sabo J, Mirossay L, Horovcak L et al (2002) Effects of static magnetic field on human leukemic cell line HL-60. Bioelectrochemistry 56:227–231CrossRef
  33.Vergallo C, Ahmadi M, Mobasheri H et al (2014) Impact of inhomogeneous static magnetic field (31.7–232.0 mT) exposure on human neuroblastoma SH-SY5Y cells during cisplatin administration. PLoS ONE 9:e113530CrossRef
  
• 作者单位：Lei Zhang (1) (2)
  Xingxing Yang (1)
  Juanjuan Liu (1) (2)
  Yan Luo (1)
  Zhiyuan Li (1)
  Xinmiao Ji (1)
  Wenchao Wang (1)
  Xin Zhang (1)
  
  1. High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, 230031, China
  2. University of Science and Technology of China, Hefei, 230026, China
  
• 刊物主题：Science, general; Life Sciences, general; Physics, general; Chemistry/Food Science, general; Earth Sciences, general; Engineering, general;
• 出版者：Springer Berlin Heidelberg
• ISSN：1861-9541

文摘

Static magnetic field (SMF) has been known to affect cell proliferation in a cell-type-dependent manner, while the mechanism still remains unclear. We found that 1 T moderate intensity SMF inhibits cell proliferation of nasopharyngeal carcinoma CNE-2Z cells and the Akt/mTOR signaling pathway, which is upregulated in many cancers. mTOR inhibitors are potential chemodrugs, but their clinical effects are limited by the feedback reactivation of other signaling components such as EGFR and Akt. We showed that 1 T SMF increases the antitumor efficacy of mTOR inhibitor Torin 2. In addition, 1 T SMF increases the inhibition efficiency on mTOR substrates phosphorylation and represses the mTOR inhibitor-induced feedback reactivation of EGFR and Akt. Our study not only demonstrates that mTOR/Akt pathway is one of the molecular targets of SMFs in cells, but also reveals the clinical potentials of combinations of mTOR inhibitors and SMFs in cancer treatment. Keywords Static magnetic field Cell proliferation mTOR mTOR inhibitor Feedback reactivation